Needham & Company LLC Reiterates Buy Rating for Artiva Biotherapeutics (NASDAQ:ARTV)

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reaffirmed by research analysts at Needham & Company LLC in a report released on Tuesday,Benzinga reports. They presently have a $23.00 price target on the stock.

Separately, HC Wainwright began coverage on shares of Artiva Biotherapeutics in a research report on Monday, December 30th. They issued a “buy” rating and a $20.00 price objective on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $20.40.

Artiva Biotherapeutics Stock Down 8.8 %

NASDAQ ARTV opened at $3.64 on Tuesday. The business has a 50 day moving average price of $4.84 and a 200 day moving average price of $9.33. Artiva Biotherapeutics has a 1-year low of $3.37 and a 1-year high of $17.31.

Institutional Investors Weigh In On Artiva Biotherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets acquired a new stake in Artiva Biotherapeutics in the 3rd quarter worth about $42,000. China Universal Asset Management Co. Ltd. purchased a new position in shares of Artiva Biotherapeutics during the 4th quarter worth about $52,000. Wells Fargo & Company MN boosted its position in shares of Artiva Biotherapeutics by 64.0% in the fourth quarter. Wells Fargo & Company MN now owns 8,616 shares of the company’s stock worth $87,000 after acquiring an additional 3,361 shares during the last quarter. MetLife Investment Management LLC purchased a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $135,000. Finally, JPMorgan Chase & Co. purchased a new stake in Artiva Biotherapeutics in the third quarter valued at approximately $166,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.